177 related articles for article (PubMed ID: 17288789)
21. The use of real-time reverse transcription-PCR for prostate-specific antigen mRNA to discriminate between blood samples from healthy volunteers and from patients with metastatic prostate cancer.
Patel K; Whelan PJ; Prescott S; Brownhill SC; Johnston CF; Selby PJ; Burchill SA
Clin Cancer Res; 2004 Nov; 10(22):7511-9. PubMed ID: 15569981
[TBL] [Abstract][Full Text] [Related]
22. [Detection of PSA mRNA in prostate cancer patients' blood].
Ito T; Okubo Y; Tachibana M
Rinsho Byori; 2001 Oct; 49(10):974-7. PubMed ID: 11769474
[TBL] [Abstract][Full Text] [Related]
23. Expression analysis and clinical utility of L-Dopa decarboxylase (DDC) in prostate cancer.
Avgeris M; Koutalellis G; Fragoulis EG; Scorilas A
Clin Biochem; 2008 Oct; 41(14-15):1140-9. PubMed ID: 18586020
[TBL] [Abstract][Full Text] [Related]
24. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.
Bussemakers MJ; van Bokhoven A; Verhaegh GW; Smit FP; Karthaus HF; Schalken JA; Debruyne FM; Ru N; Isaacs WB
Cancer Res; 1999 Dec; 59(23):5975-9. PubMed ID: 10606244
[TBL] [Abstract][Full Text] [Related]
25. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
[TBL] [Abstract][Full Text] [Related]
26. Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions.
Schostak M; Miller K; Krause H; Schrader M; Kempkensteffen C; Kollermann J
Cancer Detect Prev; 2006; 30(5):449-54. PubMed ID: 17067752
[TBL] [Abstract][Full Text] [Related]
27. [Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy].
Shao Q; Song J; Zhou ZJ; Du LD
Zhonghua Nan Ke Xue; 2008 Jul; 14(7):597-601. PubMed ID: 18686378
[TBL] [Abstract][Full Text] [Related]
28. Detection of prostate specific transcripts in the peripheral blood during brachytherapy predicts postoperative PSA kinetics.
Mabjeesh NJ; Amir S; Stenger A; Chen J; Matzkin H
Prostate; 2009 Aug; 69(11):1235-44. PubMed ID: 19434652
[TBL] [Abstract][Full Text] [Related]
29. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.
Rigau M; Morote J; Mir MC; Ballesteros C; Ortega I; Sanchez A; Colás E; Garcia M; Ruiz A; Abal M; Planas J; Reventós J; Doll A
Prostate; 2010 Dec; 70(16):1760-7. PubMed ID: 20672322
[TBL] [Abstract][Full Text] [Related]
30. Transforming growth factor-beta 1 gene polymorphisms and expression in the blood of prostate cancer patients.
Faria PC; Saba K; Neves AF; Cordeiro ER; Marangoni K; Freitas DG; Goulart LR
Cancer Invest; 2007 Dec; 25(8):726-32. PubMed ID: 18058470
[TBL] [Abstract][Full Text] [Related]
31. Molecular detection of circulating cancer cells in the peripheral blood of patients with colorectal cancer by using membrane array with a multiple mRNA marker panel.
Yeh CS; Wang JY; Wu CH; Chong IW; Chung FY; Wang YH; Yu YP; Lin SR
Int J Oncol; 2006 Feb; 28(2):411-20. PubMed ID: 16391796
[TBL] [Abstract][Full Text] [Related]
32. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
33. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network.
Stephan C; Cammann H; Deger S; Schrader M; Meyer HA; Miller K; Lein M; Jung K
Urology; 2009 Oct; 74(4):873-7. PubMed ID: 19476981
[TBL] [Abstract][Full Text] [Related]
34. Highly specific detection of prostate-specific antigen-positive cells in the blood of patients with prostate cancer or benign prostatic hyperplasia, using a real-time reverse-transcription-polymerase chain reaction method with improved sensitivity.
Barbero G; Destefanis P; Procida S; Mandili G; Ulliers D; Ceruti C; Fiori C; Maule MM; Fontana D; Giribaldi G; Turrini F
BJU Int; 2008 Dec; 102(11):1566-72. PubMed ID: 18549428
[TBL] [Abstract][Full Text] [Related]
35. Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: quantitative expression analysis and evaluation of its clinical significance.
Avgeris M; Stravodimos K; Scorilas A
Prostate; 2011 Dec; 71(16):1780-9. PubMed ID: 21520157
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies.
Rydén L; Egevad L; Ekman P; Hellström M
Scand J Urol Nephrol; 2007; 41(4):302-7. PubMed ID: 17763221
[TBL] [Abstract][Full Text] [Related]
37. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R
Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261
[TBL] [Abstract][Full Text] [Related]
38. Quantitative real-time RT-PCR assay for PCA3.
Väänänen RM; Rissanen M; Kauko O; Junnila S; Väisänen V; Nurmi J; Alanen K; Nurmi M; Pettersson K
Clin Biochem; 2008 Jan; 41(1-2):103-8. PubMed ID: 17996198
[TBL] [Abstract][Full Text] [Related]
39. Quantitative real-time RT-PCR of CD24 mRNA in the detection of prostate cancer.
Schostak M; Krause H; Miller K; Schrader M; Weikert S; Christoph F; Kempkensteffen C; Kollermann J
BMC Urol; 2006 Mar; 6():7. PubMed ID: 16539730
[TBL] [Abstract][Full Text] [Related]
40. High expression of a new marker PCA-1 in human prostate carcinoma.
Konishi N; Nakamura M; Ishida E; Shimada K; Mitsui E; Yoshikawa R; Yamamoto H; Tsujikawa K
Clin Cancer Res; 2005 Jul; 11(14):5090-7. PubMed ID: 16033822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
